TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07036250: A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07036250 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07036250 Rescue Dossier →